The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Inhaled nano- and microparticles for drug delivery
Open accessAbstract
The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local drug delivery, due to the lung's favourable properties of a large surface area and high permeability. Pulmonary drug delivery possesses many advantages, including non-invasive route of administration, low metabolic activity, control environment for systemic absorption and avoids first bypass metabolism. However, because the lung is one of the major ports of entry, it has multiple clearance mechanisms, which prevent foreign particles from entering the body. Although these clearance mechanisms maintain the sterility of the lung, clearance mechanisms can also act as barriers to the therapeutic effectiveness of inhaled drugs. This effectiveness is also influenced by the deposition site and delivered dose. Particulate-based drug delivery systems have emerged as an innovative and promising alternative to conventional inhaled drugs to circumvent pulmonary clearance mechanisms and provide enhanced therapeutic efficiency and controlled drug release. The principle of multiple pulmonary clearance mechanisms is reviewed, including mucociliary, alveolar macrophages, absorptive, and metabolic degradation. This review also discusses the current approaches and formulations developed to achieve optimal pulmonary drug delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Lung Clearance of Inhaled Insoluble and Soluble Particles
OBERDÖRSTER, G. (1988) · Journal of Aerosol Medicine · doi:10.1089/jam.1988.1.289 · Cited by 157
Cited by
Therapeutic efficacy of nanoparticles and routes of administration
Chenthamara, D., Subramaniam, S., Ramakrishnan, S. G., Krishnaswamy, S., Essa, M. M., Lin, F.-H., & Qoronfleh, M. W. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0166-x · Cited by 1,055
EFSA Scientific Committee, Hardy, A., Benford, D., Halldorsson, T., Jeger, M. J., Knutsen, H. K., More, S., Naegeli, H., Noteborn, H., Ockleford, C., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5327 · Cited by 416
Abdelaziz, H. M., Gaber, M., Abd-Elwakil, M. M., Mabrouk, M. T., Elgohary, M. M., Kamel, N. M., Kabary, D. M., Freag, M. S., Samaha, M. W., Mortada, S. M., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.036 · Cited by 409
EFSA Scientific Committee, More, S., Bampidis, V., Benford, D., Bragard, C., Halldorsson, T., Hernández‐Jerez, A., Hougaard Bennekou, S., Koutsoumanis, K., Lambré, C., et al. (2021) · EFSA Journal · doi:10.2903/j.efsa.2021.6768 · Cited by 395
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Metadata
- Authors
- El-Sherbiny, I. M., El-Baz, N. M., & Yacoub, M. H.
- Venue
- Global Cardiology Science and Practice
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 2
- ISSN
- 2305-7823 (ISSN-L)
- OpenAlex
- W2010097193
- Cited by
- 236
- References
- 2
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.